Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation.
Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation.
复制标题
调节性免疫细胞在器官移植中的连续转移。
DOI：
10.3389/fimmu.2021.631365
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Nadig SN
中科院分区：
文献类型：
--
作者：
Oberholtzer N;Atkinson C;Nadig SN
慢性移植物排斥反应仍然是实体器官移植治疗终末器官衰竭的重要障碍。接受器官移植的患者通常需要在其生命期间以药理学免疫抑制剂的形式进行全身免疫抑制，使这些患者容易受到机会性感染、恶性肿瘤和其他限制使用的副作用的影响。近年来，大量的研究集中在使用基于细胞的疗法来诱导移植物耐受。诱导或过继转移调节性细胞类型，包括调节性T细胞、髓源性抑制细胞和分泌IL-10的B细胞，具有在移植受体中产生移植物特异性耐受的潜力。随着我们对其潜在机制的理解的增加和新的免疫工程技术的广泛应用，这些基于细胞的治疗策略的优化已经取得了重大进展。尽管如此，关于使用的最佳细胞类型，适当的剂量和时机以及辅助治疗，仍有许多问题有待回答。在这篇综述中，我们总结了目前正在开发的用于预防同种异体移植排斥反应的基于细胞的疗法的细胞机制，正在探索的优化这些疗法的不同策略，以及所有已完成和正在进行的涉及这些疗法的临床试验。
Chronic graft rejection remains a significant barrier to solid organ transplantation as a treatment for end-organ failure. Patients receiving organ transplants typically require systemic immunosuppression in the form of pharmacological immunosuppressants for the duration of their lives, leaving these patients vulnerable to opportunistic infections, malignancies, and other use-restricting side-effects. In recent years, a substantial amount of research has focused on the use of cell-based therapies for the induction of graft tolerance. Inducing or adoptively transferring regulatory cell types, including regulatory T cells, myeloid-derived suppressor cells, and IL-10 secreting B cells, has the potential to produce graft-specific tolerance in transplant recipients. Significant progress has been made in the optimization of these cell-based therapeutic strategies as our understanding of their underlying mechanisms increases and new immunoengineering technologies become more widely available. Still, many questions remain to be answered regarding optimal cell types to use, appropriate dosage and timing, and adjuvant therapies. In this review, we summarize what is known about the cellular mechanisms that underly the current cell-based therapies being developed for the prevention of allograft rejection, the different strategies being explored to optimize these therapies, and all of the completed and ongoing clinical trials involving these therapies.
登录
查看更多内容
影响因子：
15.9
作者：
Bashuda, H;Kimikawa, M;Okumura, K
通讯作者：
Okumura, K
影响因子：
20.3
作者：
Borsellino, Giovanna;Kleinewietfeld, Markus;Falk, Kirsten
通讯作者：
Falk, Kirsten
影响因子：
5.5
作者：
Choi, Wungrak;Ji, Yong Woo;Lee, Hyung Keun
通讯作者：
Lee, Hyung Keun
影响因子：
4.4
作者：
Almand, B;Clark, JI;Gabrilovich, DI
通讯作者：
Gabrilovich, DI
影响因子：
4.4
作者：
Dilek, Nahzli;Poirier, Nicolas;Vanhove, Bernard
通讯作者：
Vanhove, Bernard